Sociedad Americana de Hirudoterapia

Assessment of platelet biology in equine patients with systemic inflammatory response syndrome

Research article published in Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc (2020)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Preclinical (animal)Ensayos clínicosFarmacología salivalEhrmann C et al. · Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 2020

Abstract

In addition to maintaining hemostasis, platelets have an important role in modulating innate and adaptive immune responses. A low platelet count has been found to be a negative prognostic factor for survival in humans and horses with critical illnesses, such as sepsis or systemic inflammatory response syndrome (SIRS). Decreased platelet aggregation, caused by in vivo activation, has been found in human patients with severe sepsis. In our prospective controlled study, we assessed platelet biology in blood samples from 20 equine SIRS cases and 120 healthy control horses. Platelet variables such as platelet count, large platelet count, clumps, plateletcrit, mean platelet volume, and mean platelet component concentration were analyzed by laser flow cytometry (Advia 2120) from K3EDTA blood and from citrate blood. Hirudin blood samples were analyzed by impedance aggregometry (Multiplate analyzer; Roche) for platelet aggregation, including spontaneous aggregation and aggregation by 4 different agonists: adenosine diphosphate (ADPtest), ADP + prostaglandin E1 (ADPtestHS), arachidonic acid (ASPItest), and collagen (COLtest). SIRS cases had significantly lower platelet counts in K3EDTA blood (p < 0.0001) compared to control horses. There were no significant differences in aggregation values between SIRS cases and controls. Non-surviving SIRS horses did not have statistically significant lower platelet counts or lower aggregation values for COLtest, ADPtest, or ADPtestHS compared to surviving SIRS horses, although 5 non-survivors were thrombocytopenic.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsBlood PlateletsCase-Control StudiesFemaleGermanyHorse DiseasesHorsesMalePlatelet AggregationPlatelet CountProspective StudiesSystemic Inflammatory Response Syndrome

Resumen

In addition to maintaining hemostasis, platelets have an important role in modulating innate and adaptive immune responses.

Por qué esto importa para la hirudoterapia

Este estudio controlado prospectivo evaluó la biología plaquetaria —incluyendo recuentos, índices y agregación— en 20 caballos con síndrome de respuesta inflamatoria sistémica (SIRS) en comparación con 120 caballos controles sanos, utilizando sangre anticoagulada con hirudina para agregometría de impedancia (analizador Multiplate) con cuatro agonistas: ADP (ADPtest), ADP + prostaglandina E1 (ADPtestHS), ácido araquidónico (ASPItest) y colágeno (COLtest). Los casos de SIRS presentaron recuentos plaquetarios significativamente menores pero sin diferencias significativas en los valores de agregación frente a los controles. El resumen menciona la hirudina solo como el anticoagulante utilizado para las pruebas de agregación y no identifica su fuente ni menciona sanguijuelas; el estudio no involucra terapia terapéutica con sanguijuelas, y los hallazgos pertenecen a la enfermedad crítica equina.

Citación

Assessment of platelet biology in equine patients with systemic inflammatory response syndrome

Ehrmann C et al. · Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.